CLRB

Cellectar Biosciences Inc

CLRB.US cellectar.com
2.31
-0.06 (-2.53%)
USD · NASDAQ
52-week range
2.20
6.52
Trading at 3% of the 52-week range
Market Cap
21.83M
P/E Ratio
0.00
Forward P/E
0.00
Book Value
3.62
Div. Yield
N/A
% Institutions
34.71%
% Insiders
1.75%

1 Year

-56.3%

3 Year

-96.5%

10 Year

-100.0%
Description

Cellectar Biosciences, Inc., a clinical biopharmaceutical company, focuses on the discovery, development, and commercialization of drugs for the treatment of cancer in the United States. The company's lead phospholipid drug conjugate (PDC) candidate is CLR 131 (iopofosine I-131), which is in Phase 2 clinical study for patients with B-cell malignancies; Phase 2a clinical study for patients with relapsed or refractory (r/r) Waldenstrom's macroglobulinemia cohort, r/r multiple myeloma (MM) cohort, and r/r non-Hodgkin's lymphoma cohort; Phase 1 clinical study for r/r pediatric patients with select solid tumors, lymphomas, and malignant brain tumors; and Phase 1 clinical study for r/r head and neck cancer. It also develops CLR 121125, an iodine-125 Auger-emitting radioconjugate program; and CLR 225, an actinium-225 based radioconjugate program. The company has collaborative with Orano Med to develop alpha emitter lead-212 conjugated to phospholipid ether series; and LegoChem Bio. Cellectar Biosciences, Inc. was founded in 2002 and is headquartered in Florham Park, New Jersey.

Company Information

Company Name
Cellectar Biosciences Inc
Sector
Healthcare
Industry
Biotechnology
Exchange
NASDAQ
ISIN: US15117F8804
CIK: 0001279704
CUSIP: 67000M100
Currency: USD
Full Time Employees: 11
Phone: 608 441 8120
Fiscal Year End: December
IPO Date: Nov 10, 2005
Description:

Cellectar Biosciences, Inc., a clinical biopharmaceutical company, focuses on the discovery, development, and commercialization of drugs for the treatment of cancer in the United States. The company's lead phospholipid drug conjugate (PDC) candidate is CLR 131 (iopofosine I-131), which is in Phase 2 clinical study for patients with B-cell malignancies; Phase 2a clinical study for patients with relapsed or refractory (r/r) Waldenstrom's macroglobulinemia cohort, r/r multiple myeloma (MM) cohort, and r/r non-Hodgkin's lymphoma cohort; Phase 1 clinical study for r/r pediatric patients with select solid tumors, lymphomas, and malignant brain tumors; and Phase 1 clinical study for r/r head and neck cancer. It also develops CLR 121125, an iodine-125 Auger-emitting radioconjugate program; and CLR 225, an actinium-225 based radioconjugate program. The company has collaborative with Orano Med to develop alpha emitter lead-212 conjugated to phospholipid ether series; and LegoChem Bio. Cellectar Biosciences, Inc. was founded in 2002 and is headquartered in Florham Park, New Jersey.

Address:

100 Campus Drive, Florham Park, NJ, United States, 07932

People

Directors & Officers

Name Title Year Born
Mr. James V. Caruso President, CEO & Director 1959
Mr. Chad J. Kolean CPA VP, CFO & Secretary 1964
Mr. Jarrod Longcor Chief Operating Officer 1973

Insider Trading

Date Insider Name Title Transaction Type Shares Price Value
Dec 12, 2025 John Neis N/A Sale 198.00 $3.70 $732.60
Jul 02, 2025 Chad J Kolean N/A Purchase 5.00K $4.99 $24.95K
Jul 02, 2025 James V Caruso N/A Purchase 10.00K $4.99 $49.90K
Jul 02, 2025 Jarrod Longcor N/A Purchase 10.00K $4.99 $49.90K

Shareholders

Institutional Holders

Holder Name Shares Date Reported % Out Value % Change
Caligan Partners LP 470.00K Jun 30, 2026 4.97% $0.06 0.00%
Empery Asset Management, LP 189.61K Jun 30, 2026 2.01% $0.61 0.00%
Diadema Partners LP 138.34K Jun 30, 2026 1.46% $0.05 0.00%
Bleichroeder LP 100.00K Mar 31, 2026 1.06% $0.04 0.00%
Vanguard Capital Management, LLC 81.88K Mar 31, 2026 0.87% $0.00 0.00%
Geode Capital Management, LLC 52.78K Mar 31, 2026 0.56% $0.00 84.31%
Sequoia Financial Advisors LLC 21.85K Jun 30, 2026 0.23% $0.00 15.92%
Vanguard Fiduciary Trust Co 16.57K Mar 31, 2026 0.18% $0.00 0.00%
Riverview Capital Advisers LLC 10.38K Mar 31, 2026 0.11% $0.02 0.00%
UBS Group AG 9.65K Mar 31, 2026 0.10% $0.00 271.32%
BlackRock Inc 4.75K Mar 31, 2026 0.05% $0.00 0.00%
Tower Research Capital LLC 793.00 Mar 31, 2026 0.01% $0.00 -56.74%
Vanguard Global Advisers, LLC 563.00 Mar 31, 2026 0.01% $0.00 0.00%
Morgan Stanley - Brokerage Accounts 510.00 Mar 31, 2026 0.01% $0.00 0.00%
TD Waterhouse Canada Inc 63.00 Mar 31, 2026 0.00% $0.00 0.00%
SBI Securities Co Ltd 11.00 Mar 31, 2026 0.00% $0.00 0.00%
FMR Inc 10.00 Mar 31, 2026 0.00% $0.00 0.00%
U.S. Bancorp 3.00 Mar 31, 2026 0.00% $0.00 0.00%
JONES FINANCIAL COMPANIES LLLP 3.00 Mar 31, 2026 0.00% $0.00 0.00%
Danske Bank A/S. 2.00 Jun 30, 2026 0.00% $0.00 0.00%

Fund Holdings

Rank Holder Name Shares Held % of Shares Change Date Reported
1 Vanguard MStar Total Stk Mkt Idx Invest 184.15K 1.95% ▲ 0.00% Jul 31, 2026
2 Vanguard Institutional Extnd Mkt Idx Tr 143.22K 1.52% ▲ 0.00% Jul 31, 2026
3 Fidelity Extended Market Index 42.52K 0.45% ▼ 0.19% Jul 31, 2026
4 Abante Quant Value FI 36.31K 0.38% ▲ 100.97% Jul 31, 2026
5 NT Ext Equity Mkt Index Fund - NL 7.84K 0.08% ▲ 280.78% Jun 30, 2026
6 Northern Trust Extended Eq Market Idx 6.94K 0.07% ▲ 0.00% Jun 30, 2026
7 NT Ext Equity Mkt Index Fund - Lending 6.94K 0.07% ▲ 0.00% Jun 30, 2026
8 NT Ext Equity Mkt Idx Fd - DC - NL - T2 5.69K 0.06% ▲ 252.54% Jun 30, 2026
9 Fidelity Series Total Market Index 5.64K 0.06% ▲ 0.00% Jul 31, 2026
10 Spartan Total Market Index Pool A1 3.04K 0.03% ▲ 0.00% Jul 31, 2026

Financial Highlights

Market Cap: $21.83M
EBITDA: $-23.36M
PEG Ratio: $0.00
Book Value: $3.62
Earnings/Share: $-2.21
Profit Margin: 0.00%
Operating Margin: 0.00%
ROA (TTM): -58.44%
ROE (TTM): -119.57%
Revenue (TTM): $0.00
Revenue/Share (TTM): $0.00
Earnings Growth (YOY): 0.00%
Revenue Growth (YOY): 0.00%

Valuation Metrics

Enterprise Value: $-10.63M
Trailing P/E: 0.00
Forward P/E: 0.00

Shares Statistics

Shares Outstanding: 9.45M
Shares Float: 9.28M
% Insiders: 1.75%
% Institutions: 34.71%
Short % Float: 1.77%

Stock Price History

1 Year Price History

3 Years Price History

10 Years Price History

Financial Charts

Revenue, Net Income & Operating Cash Flow (Yearly)

Revenue, Net Income & Operating Cash Flow (Quarterly)

Operating Expenses (Yearly)

Operating Expenses (Quarterly)

Balance Sheet (Quarterly)

Assets Breakdown (Yearly)

Assets Breakdown (Quarterly)

Liabilities Breakdown (Yearly)

Liabilities Breakdown (Quarterly)

Income Statement Waterfall

Open full waterfall
Line Item
Step Type
Value
Revenue
adjust
$0.00
Cost of Goods Sold
adjust
$-213.60K
Gross Profit
subtotal
$-213.60K
SG&A
adjust
$-11.48M
R&D
adjust
$-11.50M
Operating Income
subtotal
$-22.98M
Other / Non-Operating Items
adjust
$1.19M
Net Income
subtotal
$-21.79M

Earnings Per Share (EPS) History

Financial Ratios

📦 Raw API Data (JSON Explorer)

Assistant

×
Hello! I'm your AI assistant. I have access to the financial data on this page. Ask me anything about CLRB.US!